Hepatocyte growth factor activator inhibitor 1 (HAI-1) is a multi-domain membrane-associated protease inhibitor that potently inhibits a variety of serine proteases such as hepatocyte growth factor activator and matriptase. Different truncates of HAI-1 show varying potencies for inhibition of target proteases, suggesting that the domain organization of HAI-1 plays a critical role in its function. Here, the soluble full-length extracellular part of HAI-1 (sHAI-1) was expressed using the Drosophila S2 insect-cell expression system. Diffractionquality crystals of sHAI-1 were produced using ammonium sulfate as precipitant. The crystal diffracted to 3.8 Å resolution and belonged to space group P4 1 2 1 2, with unit-cell parameters a = b = 95.42, c = 124.50 Å . The asymmetric unit contains one sHAI-1 molecule. research communications Acta Cryst. (2017). F73, 45-50 Liu et al. Hepatocyte growth factor activator inhibitor 1 49
Introduction
Hepatocyte growth factor activator inhibitor 1 (HAI-1) is a Kunitz-type serine protease inhibitor that was originally identified as a potent inhibitor of hepatocyte growth factor activator (HGFA; Shimomura et al., 1997) . In utero, HAI-1deficient mice die owing to undifferentiated chorionic trophoblasts (Fan et al., 2007; Hong et al., 2016) , indicating that HAI-1 is essential for placental development. After birth, HAI-1-deficient mice were found to have enhanced epithelial cell apoptosis and increased mucosal permeability (Kawaguchi et al., 2011; Itoh et al., 2000) , showing that HAI-1 is essential to maintain epithelium integrity. In addition, HAI-1 is important to maintain keratinization of the epidermis via maintaining the assembly of keratin into desmosomes in keratinocytes (Kawaguchi et al., 2015) . HAI-1 also affects the proliferation and cell fate of neural progenitor cells (Koivuniemi et al., 2013) . Abnormal HAI-1 expression levels have also been observed in various types of human cancer (Parr & Jiang, 2001; Zheng et al., 2014) . Breast, pancreatic, prostate and oral carcinoma cells exhibited enhanced invasive properties in vitro in response to HAI-1 knockdown (Parr & Jiang, 2006; Sanders et al., 2007; Baba et al., 2012; Cheng et al., 2009) . Forced expression of HAI-1 significantly inhibited the invasion and migration of cervical, endometrial and uterine cancer cells in vitro (Nakamura et al., 2010 (Nakamura et al., , 2011 . HAI-1 suppresses tumorigenesis and progression via regulation of the activity of a range of serine proteases in tumour microenvironments (Zheng et al., 2014) , including matriptase (Oberst et al., 2002) ,
# 2017 International Union of Crystallography HGFA , hepsin , prostasin , plasmin (Kirchhofer et al., 2003) , TMPRSS13 (Hashimoto et al., 2010) and human airway trypsin-like protease (HAT; Kato et al., 2012) .
HAI-1 is produced by epithelial cells as a membraneassociated form containing a MANEC PAN/apple-like domain (MANEC or N), an internal domain (I) with two Kunitz domains (K1 and K2) separated by a low-density lipoprotein receptor (LDLR)-like domain (L), a transmembrane region and a short cytoplasmic region (Shimomura et al., 1997; Fig. 1a ). The membrane-bound form of full-length HAI-1 can be liberated from the cell surface via proteolytic cleavage in the C-terminal transmembrane domain (Shimomura et al., 1999) . Several soluble forms of truncated HAI-1 have been identified in the conditioned media of cells (Shimomura et al., 1997; Tsuzuki et al., 2005) and human milk (Lin et al., 1999) , with molecular weights of 58, 40/39 and 25 kDa, respectively (Shimomura et al., 1999; Lin et al., 1999) . In vitro, soluble forms of recombinant HAI-1 variants made up of various combinations of domains have different inhibitory activities, indicating different roles of these domains in protease inhibition (Kojima et al., 2008) .
Structural studies of HAI-1 are limited and are restricted to HAI-1 fragments. Crystal structures of the HAI-1 IK1 fragment (Hong et al., 2016) , the HAI-1 K1-matriptase complex (Zhao et al., 2013) , the HAI-1 K1-HGFA complex (Shia et al., 2005) and an NMR structure of the MANEC domain (Hong et al., 2015) have been reported. However, how HAI-1 arranges its domains in space and regulates its inhibitory activity remains unclear and needs to be illustrated in detail. Here, we report the purification, crystallization and diffraction of the full-length extracellular domain of HAI-1 (sHAI-1; NIK1LK2; Fig. 1a ) in order to study the molecular mechanism of its regulation of inhibitory activity.
Materials and methods

Macromolecule production
The cDNA for sHAI-1 (residues Gly36-Phe441) was generated by PCR using the full-length cDNA of HAI-1 isoform 2 (Fig. 1a) , and was digested with the MluI restriction enzyme (Zhao et al., 2013) . The digested fragments were cloned into the expression vector pMT/Bip/V5-His-A (Invitrogen), which was digested with the SmaI and MluI restriction enzymes ( Table 1 ). The sequence of the final expression vector pMT/Bip/sHAI-1 was confirmed by DNA sequencing. A total of 2 mg expression vector (pMT/Bip/sHAI-1) and selection vector pCoBlast (Invitrogen) were mixed in a ratio of 19:1 and the mixture was co-transfected into exponentially growing Drosophila S2 cells (Invitrogen) using Cellfectin II reagent (Invitrogen) according to the manufacturer's instructions. Blasticidin (Invitrogen) was added to the medium to a final concentration of 25 mg ml À1 2 d after transfection to select stable cell lines. The selection medium was replaced every 3 d, and stably transformed polyclonal cell populations were isolated after 9 d. For large-scale production, stably transfected S2 cells were cultured in EX-CELL-420 serum-free medium (Sigma-Aldrich) at 25 C and 120 rev min 10 6 cells per millilitre, a final concentration of 500 mM CuSO 4 was added for induction of expression. The conditioned medium was harvested after one week of incubation. The cultured supernatant was clarified by centrifugation at 1000 rev min À1 for 10 min at 4 C, and the supernatant was centrifuged again at 10 000 rev min À1 for 30 min at 4 C. Before purification, the supernatant was filtered through a 0.45 mm filter membrane. The recombinant protein was captured by Ni Sepharose Excel resin (GE Healthcare Life Sciences). After washing with buffer containing 10 mM imidazole, the target protein was finally eluted with elution buffer consisting of 200 mM imidazole, 50 mM Tris-HCl pH 8.0 ( Fig. 1b ). Fractions containing sHAI-1 protein were pooled and dialyzed into buffer consisting of 50 mM Tris-HCl pH 8.0 for further purification. Using Resource Q anion-exchange chromatography (GE Healthcare Life Sciences), the eluted protein was further purified with a linear gradient of 50-300 mM NaCl at pH 8.0 (Fig. 1c ). The peak fractions were concentrated and further purified using size-exclusion chromatography (Superdex 75 10/300 GL) with elution buffer consisting of 50 mM Tris-HCl pH 8.0 (Fig. 1d) . The sHAI-1 protein was concentrated to 40 mg ml À1 for crystal-growth experiments. The cDNA of the HAI-1 K1 domain (residues Ser245-Val303; Table 2 ) was also generated by PCR using the full-length cDNA of HAI-1 isoform 2 as a template. PCR products were digested with EcoRI and SalI restriction enzymes and were then cloned into the pPICZA expression vector (Invitrogen; Table 2 ). The recombinant plasmid encoding HAI-1 K1 was linearized with the MssI restriction enzyme and transformed into Pichia pastoris X-33 cells (Invitrogen) by electroporation (1500 V, 25 mF, 200). The positive transformants were selected on a YPDS plate (1% yeast extract, 2% tryptone, 2% glucose, 1 M sorbitol, 1.2% agarose) containing 100 mg ml À1 Zeocin at 28 C for 2 d. For protein expression, the expression clones were inoculated into 100 ml BMGY medium (1% yeast extract, 2% tryptone, 1% glycerol, 100 mM potassium phosphate pH 6.0) until the culture reached an A 600 of 6. The cells were harvested by centrifugation at 1500 rev min À1 for 5 min at room temperature and resuspended in 500 ml BMMY medium (1% yeast extract, 2% tryptone, 0.5% methanol, 100 mM potassium phosphate pH 6.0). The cultures were then induced every 24 h with 1%(v/v) methanol for 4 d. Target protein was captured using Ni Sepharose Excel resin and was eluted with 200 mM imidazole in 50 mM Tris-HCl pH 8.0. Fractions containing HAI-1 K1 protein were pooled and concentrated to 0.5 mg ml À1 for further use. All fractions were analysed on 12% polyacrylamide gels, and proteins were stained with Coomassie Brilliant Blue R-250.
The inhibitory activities of sHAI-1 and its fragment (HAI-1 K1) against the serine protease domain of matriptase (matriptase-SPD) were determined by a chromogenic assay in a reaction buffer consisting of 150 mM NaCl, 0.5% Tween 20, 
Figure 2
Inhibition arrays of sHAI-1 (a) and HAI-1-K1 (b) against matriptase-SPD measured using the chromogenic assay. 20 mM Tris-HCl pH 7.4. sHAI-1 with an initial concentration of 6 mg ml À1 was serially diluted in a ratio of 1:3 using the reaction buffer, and 10 ml of each diluted sample was then incubated with matriptase-SPD at room temperature for 10 min in a 96-well polystyrene plate. The proteolytic reactions were initiated by adding 40 mM of the chromogenic substrate Pefachrome tPA to the system to a final volume of 100 ml. The kinetics of p-nitroanilide release were monitored spectrophotometrically at 405 nm for 10 min (Fig. 2) .
Crystallization
We screened more than 1000 crystallization conditions using a Phoenix crystallization robot (Art Robbins Instruments) with commercial screening kits (from Qiagen, XtalQuest and Hampton Research) by the sitting-drop vapour-diffusion method, and obtained preliminary crystals of sHAI-1 with a tetrahedral morphology. Reproducible crystals were finally obtained in 1.6 M ammonium sulfate, 20%(v/v) glycerol, 0.08 M sodium acetate pH 4.6 after 7 d at 25 C (Fig. 3a) . Crystals were picked up from the drop, washed with reservoir solution, dissolved in SDS-PAGE loading buffer and subsequently checked by SDS-PAGE (Fig. 3b ). After optimization, the final diffraction-quality crystals of sHAI-1 were soaked briefly in a cryoprotectant solution consisting of 1.8 M ammonium sulfate, 0.08 M sodium acetate pH 4.6 with 25%(v/v) glycerol prior to data collection (Table 3) . These crystals were cooled in liquid nitrogen for X-ray data collection.
Data collection and processing
Data collection was performed under cryogenic conditions at 100 K on beamline BL18U1 at Shanghai Synchrotron Radiation Facility (SSRF). A total of 720 images were collected at a crystal-to-detector distance of 300 mm with 2 s exposure time for every 0.5 oscillation frame. The data were processed using the HKL-3000 package (Minor et al., 2006) . Data-collection and processing statistics are summarized in Table 4 . Crystallization and X-ray data collection of sHAI-1. (a) Crystals of sHAI-1 obtained using 1.6 M ammonium sulfate, 20%(v/v) glycerol, 0.08 M sodium acetate pH 4.6. (b) SDS-PAGE analysis of sHAI-1 crystals reveals no degradation during crystallization. Lane 1 contains sHAI-1 used in the crystallization experiment and lane 2 contains dissolved sHAI-1 crystals. (c) The X-ray diffraction pattern of the sHAI-1 crystal to 3.8 Å resolution. 
Results and discussion
We constructed the expression vector for sHAI-1 with a hexa-His tag, and transfected it into Drosophila S2 cells. The secretory expression level of sHAI-1 was up to 80 mg per litre of culture. The target protein was initially captured and purified using Ni Sepharose Excel resin and fractions containing sHAI-1 protein were confirmed by SDS-PAGE (purity of $85%; Fig. 1b) . A subsequent anion-exchange chromatographic purification (Resource Q) further increased the purity of the sHAI-1 protein (to $90%; Fig. 1c ). Fractions containing sHAI-1 were pooled, concentrated and applied onto a gel-filtration column (Superdex 75 10/300), and the target protein was collected and concentrated to 40 mg ml À1 . SDS-PAGE analysis revealed that sHAI-1 was homogenous with high purity (up to 95%; Fig. 1d ). The target protein was shown to exist in a monomeric form based on its elution volume (10.5 ml) on Superdex 75 (Fig. 1d ). The IC 50 value of sHAI-1 towards matriptase-SPD was 160-fold weaker than that of the isolated HAI-1 K1 fragment (Fig. 2) , demonstrating that the full-length extracellular domain of HAI-1 was less potent in inhibition of matriptase, which was consistent with a previous study with rat HAI-1 and matriptase (Kojima et al., 2008) .
To investigate the role of the domains in the regulation of the inhibitory activity of sHAI-1, sHAI-1 was crystallized in 1.6 M ammonium sulfate, 20%(v/v) glycerol, 0.08 M sodium acetate pH 4.6 using the sitting-drop vapour-diffusion method (Table 3 and Fig. 3a ). SDS-PAGE analysis of the crystals showed only a single band near 54 kDa (Fig. 3b) ; thus, no degradation took place during crystallization. This result was encouraging because degradation was a large problem in our previous work on this protein (Zhao et al., 2013) .
The initial crystals of sHAI-1 were too small and diffracted to only 7-8 Å resolution. Intensive efforts were made to improve the resolution, including trying different additives (e.g. calcium) or pH, decreasing the concentration of sHAI-1 protein to 20 mg ml À1 , changing the concentration of glycerol to 4% and screening different cryoprotectants. Finally, a data set to moderate resolution (3.8 Å ) was obtained on beamline BL18U1 at Shanghai Synchrotron Radiation Facility (SSRF; Fig. 3c ) using the best cryoprotection, which consisted of the reservoir solution containing 25%(v/v) glycerol (Table 3 ). The crystal belonged to space group P4 1 2 1 2, with unit-cell parameters a = b = 95.42, c = 124.50 Å . The asymmetric unit contained one sHAI-1 molecule (54 kDa) with approximately 53% solvent content and a Matthews coefficient (V M ) of 2.62 Å 3 Da À1 (Matthews, 1968) . We are working towards phase solution by molecular replacement. The relatively low resolution of the crystal is likely to be owing to the multidomain nature of this protein. Fortunately, we are able to obtain molecular-replacement solutions for most domains. Further structural analysis is currently under way.
